Murdo Gordon, Executive Vice President of Global Commercial Operations at Amgen Inc . (NASDAQ:AMGN), recently sold a significant portion of the company's stock. According to a filing with the ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Unusually, Amgen acknowledges the quandary in its press release about the US FDA approval of Repatha, where Anthony Hooper, the company's vice president of commercial operations, says the company ...

Amgen has been a biotechnology pioneer since ... commercialisation of development programs and lifecycle management of commercial products. "...the industry will continue to face the challenges ...

Before you buy stock in Amgen, consider this ... teams reliably delivered quality results across the portfolio, and our commercial teams grew the business across our four therapeutic areas ...

The global company says it will eventually employ 700 at its Wake County factories. STORY HIGHLIGHTS Amgen completed a $550 million facility in Holly Springs. Company has started construction on a ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...